MedPath

陕西丽彩药业有限公司

Ownership
-
Established
2003-12-29
Employees
-
Market Cap
-
Website
www.licaiyaoye.com

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

28

NMPA:28

Drug Approvals

Nicardipine Hydrochloride Injection

Product Name
盐酸尼卡地平注射液
Approval Number
国药准字H20253423
Approval Date
Feb 20, 2025
NMPA

Betamethasone Sodium Phosphate Injection

Product Name
倍他米松磷酸钠注射液
Approval Number
国药准字H20253417
Approval Date
Feb 20, 2025
NMPA

Metoclopramide Hydrochloride Injection

Product Name
盐酸甲氧氯普胺注射液
Approval Number
国药准字H20253061
Approval Date
Jan 2, 2025
NMPA

Pranoprofen Eye Drops

Product Name
普拉洛芬滴眼液
Approval Number
国药准字H20253051
Approval Date
Jan 2, 2025
NMPA

Acetylcysteine Solution for Inhalation

Product Name
吸入用乙酰半胱氨酸溶液
Approval Number
国药准字H20249497
Approval Date
Dec 1, 2024
NMPA

Drotaverine Hydrochloride Injection

Product Name
盐酸屈他维林注射液
Approval Number
国药准字H20249323
Approval Date
Nov 15, 2024
NMPA

Lornoxicam for Injection

Product Name
注射用氯诺昔康
Approval Number
国药准字H20249091
Approval Date
Oct 16, 2024
NMPA

Methocarbamol Injection

Product Name
美索巴莫注射液
Approval Number
国药准字H20249041
Approval Date
Oct 9, 2024
NMPA

Famotidine Injection

Product Name
法莫替丁注射液
Approval Number
国药准字H20244976
Approval Date
Sep 26, 2024
NMPA

Tafluprost Eye Drops

Product Name
他氟前列素滴眼液
Approval Number
国药准字H20244914
Approval Date
Sep 19, 2024
NMPA
  • Prev
  • 1
  • 2
  • 3
  • Next

Clinical Trials

No trials found

News

No news found
© Copyright 2025. All Rights Reserved by MedPath